Skip to main content

Market Overview

Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M

Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
  • Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.
  • Under the terms of the agreement, all pending patent and non-patent claims have been resolved between plaintiff BD and codefendants Qiagen and former officers of NeuMoDx.
  • BD will receive a one-time, lump-sum payment of $53 million. The agreement includes general releases of all parties with no admissions of wrongdoing.
  • BD in 2019 alleged NeuMoDx, then an independent company but under a merger agreement with Qiagen, had infringed on several US patents covering technologies surrounding the use of microfluidic cartridges for molecular diagnostic assays and instruments.
  • NeuMoDx filed counterclaims and affirmative defense, namely that certain patents were invalid and unenforceable under US patent laws due to prior art and obviousness. 
  • Qiagen said that the settlement does not affect its outlook for net sales and adjusted EPS for Q4 and FY21.
  • Related: Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance
  • Price Action: BDX shares closed at $243.71 on Friday, while QGEN closed at $54.24.

Related Articles (QGEN + BDX)

View Comments and Join the Discussion!

Posted-In: BriefsNews Health Care Legal Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at